Leap Therapeutics (LPTX) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning. The brokerage currently has $7.00 target price on the stock.

According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “

Leap Therapeutics (NASDAQ LPTX) opened at $6.27 on Wednesday. Leap Therapeutics has a one year low of $4.90 and a one year high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Monday, November 13th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). research analysts anticipate that Leap Therapeutics will post -3.63 earnings per share for the current fiscal year.

In related news, COO Augustine Lawlor bought 1,057,769 shares of Leap Therapeutics stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average cost of $6.09 per share, with a total value of $6,441,813.21. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 58.40% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/06/leap-therapeutics-lptx-upgraded-at-zacks-investment-research.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Leap Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Leap Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit